Summary

According to the recently published report ’Cyclin Dependent Kinase 4 - Drugs In Development, 2022’; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 52 molecules. Out of which approximately 49 molecules are developed by companies and remaining by the universities/institutes.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

The report ’Cyclin Dependent Kinase 4 - Drugs In Development, 2022’ outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 6, 10, 3, 15 and 7 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Infectious Disease, Toxicology, Undisclosed and Genetic Disorders which include indications Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Solid Tumor, Breast Cancer, Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Mantle Cell Lymphoma, Colorectal Cancer, Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer, Ovarian Cancer, Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Prostate Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Bladder Cancer, Central Nervous System (CNS) Cancer, Colon Cancer, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, High-Grade Glioma, Liposarcoma, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Oligodendroglioma, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Astrocytoma, Chemotherapy Induced Myelosuppression, Chronic Lymphocytic Leukemia (CLL), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Epithelial Ovarian Cancer, Follicular Lymphoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroblastoma, Neuroendocrine Tumors, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Small-Cell Lung Cancer, Thymic Carcinoma, Unspecified, Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy-Induced Diarrhea (CID), Chordoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Hormone Sensitive Breast Cancer, Hormone-Sensitive Prostate Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hypopharyngeal Cancer, Kaposi Sarcoma, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Liver Cancer, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Neurofibromatoses Type I (Von Recklinghausen’s Disease), Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial), Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) and Well Differentiated Liposarcoma.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics




Reasons To Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope